ClinicalTrials.gg
Not yet recruitingNCT07913061Updated Nov 3, 2026

A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin

A Phase 3 interventional study of SHR-3167 and insulin degludec in Diabetes Mellitus, Type 2, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
4th of 81
680 · median 80
Started
2026
with 6 others
Phase 3
18 of 81
3 open now
Primary completion
2028-01
later than 10 of 10 live
Registered
80th of 81
by date

Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 4th largest by planned enrollment, is one of 7 that started in 2026, is one of 18 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 80th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of once-weekly SHR-3167 and once-daily Insulin Degludec in participants with Type 2 diabetes that has been treated with basal insulin. The study consists of a screening period, a treatment period and a safety follow-up period. The study will last up to 33 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, Age≥18 years old at the time of signing .
  2. Diagnosed with type 2 diabetes mellitus (T2DM) for at least 180 days prior to day of screening.
  3. Treatment with basal insulin with or without oral antidiabetic drugs at least 90 days prior to day of screening.
  4. 7.0% ≤ ≤ 10.0% at screening.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled hypertension(with or without antihypertensive treatment) : systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg at screening.
  2. Diagnosed or suspected with type 1 diabetes mellitus, latent diabetes mellitus in adult (LADA), other special types of diabetes or secondary diabetes.
  3. Known or suspected allergy or intolerance to the test drug or .
  4. Have a history of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the previous 6 months.
  5. Have acute or chronic hepatitis, liver cirrhosis, or a history of other serious liver diseases other than non-alcoholic fatty liver disease.
  6. Have hyperthyroidism (including clinical hyperthyroidism and subclinical hyperthyroidism), regardless of whether it is in the treatment stage; or hypothyroidism that requires treatment (those who have received a stable dose of thyroid hormone replacement therapy for ≥ 90 days and are willing to continue the stable treatment during the trial are excluded).
  7. within 5 years prior to screening or high risk of recurrence.
  8. Have a history of severe cardiovascular and cerebrovascular diseases within 6 months before screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
680 participants (estimated)

Study arms

  • Experimental
    SHR-3167 Group

    SHR-3167.

    Drug: SHR-3167

  • Active comparator
    Insulin Degludec Group

    Insulin degludec.

    Drug: insulin degludec

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Glycated Hemoglobin A1c (HbA1c) (Non-inferiority)

    Change from baseline in HbA1c after 26 weeks of treatment.

    Time frame: From baseline to Week 26.

Secondary outcomes

  1. Hypoglycemia Event Rate during the treatment period

    Both during the day and at night.

    Time frame: From baseline to Week 26.

  2. Adverse events (AEs)

    Evaluated by laboratory tests, electrocardiogram and vital signs, etc.

    Time frame: From baseline to Week 26.

07

Study locations

2 sites
  • The Third Affiliated Hospital of Sun Yat-sen University
    Shenzhen, Guangdong 510000, China
    • Yanming Chen · Principal investigator
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200032, China
    • Xiaoying Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913061
Responsible party
Sponsor
First posted
Nov 3, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Nan Xia
Contact
nan.xia.nx1@hengrui.com
+86-0518-82342973
Guangming Feng
Contact
guangming.feng@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-3167

Start the discussion